By focusing on the genetics of rare diseases, we make innovative new therapies possible.
Through its genetic research into rare diseases, XENON® helps create new medicines that improve the lives of patients and their families. Using our genetics platform and working with leading geneticists, doctors and collaborators from around the world, we have defined inherited mutations for rare gene disorders and extreme genetic traits (phenotypes). These provide insights into key disease processes and the root cause of a disease, which we believe will allow us to develop better medicines.
Our research and development focuses on areas of important unmet medical need, including pain, anemia, metabolic, and cardiovascular disease. Our rich pipeline spans discovery research to later-stage clinical development and addresses both niche (orphan) and common indications — through proprietary development and seven revenue-generating partnerships with leading pharmaceutical and biotechnology companies. Our partnered product Glybera® was recently became the first approved gene therapy in a regulated country and will be marketed to treat the orphan disease lipoprotein lipase deficiency.
June 10, 2013 – Xenon Licenses Antisense Drug XEN701 from Isis and Initiates Preclinical Toxicology Studies
June 2, 2013 – Xenon to participate in the Jefferies Global Healthcare Conference June 3 – 6 in New York
May 21, 2013 – Xenon to participate in the Bloom Burton & Co. Healthcare Investor Conference May 22 in Toronto
April 29, 2103 – Xenon to participate in the 12th Annual Needham Healthcare Conference April 30 to May 1 in New York
April 23, 2013 – Teva and Xenon announce FDA orphan drug designation for pain drug XEN402